VERU INC.

VERU · Nasdaq · SIC 2834: Pharmaceutical Preparations
316
SEC Filings

Business Summary

Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases. Its pipeline includes enobosarm, an oral selective androgen receptor modulator (SARM) being developed to enhance GLP-1 RA weight loss by preserving lean mass and reducing fat, and sabizabulin, a microtubule disruptor for atherosclerotic cardiovascular disease inflammation. On December 30, 2024, Veru sold its FDA-approved FC2 Female Condom commercial product.

Next Earnings

Q2 FY2026 — expected 2026-09-16

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionVERUdiscussed_in_filing Cybersecurity
topic_mentionVERUdiscussed_in_filing Trusted Computing
topic_mentionVERUdiscussed_in_filing Blockchain & Crypto
topic_mentionVERUdiscussed_in_filing Regulation
topic_mentionVERUdiscussed_in_filing Enterprise
topic_mentionVERUdiscussed_in_filing Healthcare & Bio
topic_mentionVERUdiscussed_in_filing Sovereign & Government
topic_mentionVERUdiscussed_in_filing Cybersecurity
topic_mentionVERUdiscussed_in_filing Trusted Computing
topic_mentionVERUdiscussed_in_filing Blockchain & Crypto
topic_mentionVERUdiscussed_in_filing Regulation
topic_mentionVERUdiscussed_in_filing Enterprise
topic_mentionVERUdiscussed_in_filing Healthcare & Bio
topic_mentionVERUdiscussed_in_filing Sovereign & Government
topic_mentionVERUdiscussed_in_filing Cybersecurity
topic_mentionVERUdiscussed_in_filing Trusted Computing
topic_mentionVERUdiscussed_in_filing Blockchain & Crypto
topic_mentionVERUdiscussed_in_filing Regulation
topic_mentionVERUdiscussed_in_filing Enterprise
topic_mentionVERUdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-12-172025-09-300001437749-25-038089EDGAR73K words
2024-12-162024-09-300001437749-24-037576EDGAR—
2023-12-082023-09-300000863894-23-000017EDGAR—
2022-12-052022-09-300000863894-22-000017EDGAR—
2021-12-022021-09-300000863894-21-000013EDGAR—
2020-12-102020-09-300000863894-20-000021EDGAR—
2019-12-122019-09-300000863894-19-000014EDGAR—
2018-12-132018-09-300000863894-18-000011EDGAR—
2018-01-022017-09-300001562762-17-000231EDGAR—
2016-12-122016-09-300000863894-16-000032EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-112025-12-310001437749-26-003725EDGAR26K words
2025-08-122025-06-300001437749-25-026072EDGAR—
2025-05-082025-03-310001437749-25-015330EDGAR—
2025-02-132024-12-310001437749-25-003734EDGAR—
2024-08-082024-06-300001437749-24-025338EDGAR—
2024-05-082024-03-310000863894-24-000011EDGAR—
2024-04-012023-12-310000863894-24-000008EDGAR—
2023-08-102023-06-300000863894-23-000009EDGAR—
2023-05-112023-03-310000863894-23-000006EDGAR—
2023-02-092022-12-310000863894-23-000003EDGAR—
2022-08-112022-06-300000863894-22-000013EDGAR—
2022-05-122022-03-310000863894-22-000009EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-130001437749-26-008216EDGAR14K words
2026-02-110001193125-26-045527EDGAR—
2025-12-170001193125-25-321663EDGAR—
2025-10-300001193125-25-258565EDGAR—
2025-09-260001437749-25-029912EDGAR—
2025-08-270001437749-25-027858EDGAR—
2025-08-120001437749-25-026037EDGAR—
2025-08-120001193125-25-178463EDGAR—
2025-07-250001437749-25-023521EDGAR—
2025-05-080001193125-25-115453EDGAR—

316 total filings indexed. 284 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

cardiometabolic-diseases inflammatory-diseases obesity-treatment cardiovascular-atherosclerotic-disease

Company Identity

CIK0000863894
TickerVERU
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedWI

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 3771eab3e28fa1f64a12c914e1de63c64bf8396ac63353049dc3343f8c910c34
parent: 81bc3c303165132dc76603392b01315cb4ab20947fc0c4f5c3e4fda746d2d33e
content hash: 04112de1c2f5028687f54d06036df846682964f13054d22c69a4e1ad78c37531
signed: 2026-04-13T04:48:04.327Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf